181 related articles for article (PubMed ID: 25963001)
1. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare.
Marti JL; Davies L; Haymart MR; Roman BR; Tuttle RM; Morris LG
Thyroid; 2015 Jul; 25(7):865-6. PubMed ID: 25963001
[No Abstract] [Full Text] [Related]
2. The rationale of patients with early-stage papillary thyroid cancer for accepting or rejecting radioactive iodine remnant ablation.
Sawka AM; Rilkoff H; Tsang RW; Brierley JD; Rotstein L; Ezzat S; Asa SL; Segal P; Kelly C; Zahedi A; Gafni A; Goldstein DP
Thyroid; 2013 Feb; 23(2):246-7. PubMed ID: 23009127
[No Abstract] [Full Text] [Related]
3. The 2009 American Thyroid Association guidelines modestly reduced radioactive iodine use for thyroid cancers less than 1 cm.
Roman BR; Feingold JH; Patel SG; Shaha AR; Shah JP; Tuttle RM; Epstein AJ
Thyroid; 2014 Oct; 24(10):1549-50. PubMed ID: 25065817
[No Abstract] [Full Text] [Related]
4. Application of the new American Thyroid Association guidelines leads to a substantial rate of completion total thyroidectomy to enable adjuvant radioactive iodine.
Kluijfhout WP; Pasternak JD; Drake FT; Beninato T; Shen WT; Gosnell JE; Suh I; C L; Duh QY
Surgery; 2017 Jan; 161(1):127-133. PubMed ID: 27855968
[TBL] [Abstract][Full Text] [Related]
5. Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.
Sohn SY; Choi JY; Jang HW; Kim HJ; Jin SM; Kim SW; Suh S; Hur KY; Kim JH; Chung JH; Kim SW
Thyroid; 2013 Jun; 23(6):741-7. PubMed ID: 23205883
[TBL] [Abstract][Full Text] [Related]
6. Too Much of a Good Thing: Radioactive Iodine Ablation Use for Micropapillary Thyroid Carcinoma.
Chae AW; Martinez SR
Am Surg; 2018 May; 84(5):637-643. PubMed ID: 29966562
[TBL] [Abstract][Full Text] [Related]
7. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
8. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
9. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
[TBL] [Abstract][Full Text] [Related]
10. Use of evidence-based guidelines reduces radioactive iodine treatment in patients with low-risk differentiated thyroid cancer.
Sacks W; Wong RM; Bresee C; Braunstein GD
Thyroid; 2015 Apr; 25(4):377-85. PubMed ID: 25578116
[TBL] [Abstract][Full Text] [Related]
11. Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration.
Patel SS; Goldfarb M
J Surg Oncol; 2013 May; 107(6):665-72. PubMed ID: 23192391
[TBL] [Abstract][Full Text] [Related]
12. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
13. The impact of socioeconomic status on the use of adjuvant radioactive iodine for papillary thyroid cancer.
Zevallos JP; Xu L; Yiu Y
Thyroid; 2014 Apr; 24(4):758-63. PubMed ID: 24378070
[TBL] [Abstract][Full Text] [Related]
14. Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer.
Nixon IJ; Ganly I
Future Oncol; 2013 Jul; 9(7):921-3. PubMed ID: 23837752
[No Abstract] [Full Text] [Related]
15. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?
Rosario PW
Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373
[No Abstract] [Full Text] [Related]
16. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension.
Sawka AM; Straus S; Rodin G; Thorpe KE; Ezzat S; Gafni A; Goldstein DP
Trials; 2015 Jul; 16():302. PubMed ID: 26169592
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy with 131-iodine in patients with elevated serum thyroglobulin after reoperation due to papillary thyroid carcinoma lymph node metastases.
Rosario PW; Mourão GF; Siman TL; Calsolari MR
Endocrine; 2015 May; 49(1):279-82. PubMed ID: 25205448
[No Abstract] [Full Text] [Related]
18. Patterns of use and cost for inappropriate radioactive iodine treatment for thyroid cancer in the United States: use and misuse.
Goffredo P; Thomas SM; Dinan MA; Perkins JM; Roman SA; Sosa JA
JAMA Intern Med; 2015 Apr; 175(4):638-40. PubMed ID: 25686394
[No Abstract] [Full Text] [Related]
19. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
20. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]